Corrigendum to "Effects of a static magnetic field on audiogenic seizures in black Swiss mice" [Epilepsy Res. 80 (2-3) (2008) 119-131] (DOI:10.1016/j.eplepsyres.2008.03.022);Effects of a static magnetic field on audiogenic seizures in black Swiss mice

Epilepsy Research

Volumn 80, Issue 2-3, 2008, Pages 119-131

  McLean, Michael J ^a   Engström, Stefan ^a   Qinkun, Zhang ^a   Spankovich, Christopher ^a   Polley, Daniel ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Animal seizure model; Audiogenic seizures; Auditory brainstem response; EEG; Permanent magnets; Static magnetic field

Indexed keywords

PHENYTOIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; AUDITORY STIMULATION; AUDITORY THRESHOLD; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; EVOKED BRAIN STEM AUDITORY RESPONSE; MAGNETIC FIELD; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD; SEX DIFFERENCE; SOUND INTENSITY; WHITE NOISE;

EID: 47549097344     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.05.001     Document Type: Erratum

References (65)

1. In: Barnothy M.F. (Ed). Biological Effects of Magnetic Fields (1964), Plenum Press, New York
2. Brodie M.J., Richens A., and Yuen A.W.C. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345 (1995) 476-479
3. Carlezon W.A., Rohan M.L., Mague S.D., Meloni E.G., Parsegian A., Cayetano K., Tomasciewicz H.C., Rouse E.D., Cohen B.M., and Renshaws P.F. Anti-depressant-like effects of cranial stimulation within a low-energy magnetic field in rats. Biol. Psychiatry 57 (2005) 571-576
4. Chadwick D.W., Anhut H., Greiner M.J., Alexander J., Murray G.H., Garofalo E.A., and Pierce M.W. International Gabapentin Monotherapy Study Group 945-77 A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 51 (1998) 1282-1288
5. Chaovalitwongse W., Iasemidis L.D., Pardalos P.M., Carney P.R., Shiau D.-S., and Sackellares J.C. Performance of a seizure warning algorithm based on the dynamics of intracranial EEG. Epilepsy Res. 64 (2005) 93-113
6. Dailey J.W., Reigel C.E., Mishra P.K., and Jobe P.C. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res. 3 1 (1989) 3-17
7. Dailey J.W., Yan Q.S., Adams-Curtis L.E., Ryu J.R., Ko K.H., Mishra P.K., and Jobe P.C. Neurochemical correlates of antiepileptic drugs in the genetically epilepsyprone rat (GEPR). Life Sci. 58 4 (1996) 259-266
8. De Herdt V., Boon P., Ceulemans B., Hauman H., Lagae L., Legros B., Sadzot B., Van Bogaert P., van Rijckevorsel K., Verhelst H., and Vonck K. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur. J. Paediat. Neurol. 11 (2007) 261-269
9. Engström S. Physical mechanisms of non-thermal extremely low frequency magnetic field effects. Radio Sci. Bull. 311 (2004) 96-106
10. Engström S. Magnetic field effects on free radical reactions in biology. In: Barnes F.S., and Greenebaum B. (Eds). Bioengineering and Medical Aspects of Electromagnetic Fields (2006), CRC Press, Boca Raton, FL and New York, NY 157-168
11. Faingold C.L., Walsh E.J., Maxwell J.K., and Randall M.E. Audiogenic seizure severity and hearing deficits in the genetically epilepsy-prone rat. Exp. Neurol. 108 (1990) 55-60
12. Faingold C.L. Neuronal networks in the genetically epilepsy-prone rat. In Jasper's Basic Mechanisms of the Epilepsies, third edition: Advances in neurology 79 (1999) pp. 311-321
13. French J. Refractory epilepsy: one size does not fit all. Epilepsy Curr. 6 6 (2006) 177-180
14. Freeman J.M., and Vining E.P.G. Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch. Pediatr. Adolesc. Med. 153 (1999) 946-949
15. Frings H., and Frings M. Development of strains of albino mice with predictable susceptibilities to audiogenic seizures. Sci., New Ser. 117 3037 (1953) 283-284
16. Gasior M., Rogawski M.A., and Hartman A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 17 5-6 (2006) 431-439
17. Guekht A.B., Mitrokhina T.V., Lebedeva A.V., Dzugaeva F.K., Milchakova L.E., Lokshina O.B., Feygina A.A., and Gusev E.I. Factors influencing on quality of life in people with epilepsy. Seizure 16 2 (2007) 128-133
18. Helmers S.L., Griesemer D.A., Dean J.C., Sanchez J.D., Labar D., Murphy J.V., Bettis D., Park Y.D., Shuman R.M., and Morris III G.L. Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: patients with seizures for 6 years or less. Neurologist 9 (2003) 160-164
19. Huffman J., and Kossoff E.H. State of the ketogenic diet(s) in epilepsy. Curr. Neurol. Neurosci. Rep. 6 4 (2006) 332-340
20. Jobe P.C., Mishra P.K., Browning R.A., Wang C., Adams-Curtis L.E., Ko K.H., and Dailey J.W. Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res. Bull. 35 5-6 (1994) 493-504
21. Johnsen S., and Lohmann K.J. The physics and neurobiology of magnetoreception. Nat. Rev. Neurosci. 6 (2005) 703-712
22. frings mutation underlies early onset hearing impairment in BUB/BnJ mice, a model for the auditory pathology of Usher syndrome IIC. Genomics I 85 (2005) 582-590
23. Johnson K.R., Zheng Q.Y., and Noben-Trauth K. Strain background effects and genetic modifiers of hearing in mice. Brain Res. 1091 (2006) 79-88
24. Kim Y.D., Heo K., Park S.C., Huh K., Chang J.W., Choi J.U., Chung S.S., and Lee B.I. Antiepileptic drug withdrawal after successful surgery for intractable temporal lob epilepsy. Epilepsia 46 2 (2005) 251-257
25. Klein B.D., Fu Y.-H., Ptacek L.J., and White H.S. Auditory deficits associated with the Frings Mgr1 (Mass1) mutation in mice. Dev. Neurosci. 27 (2005) 321-332
26. Kossoff E.H. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3 (2004) 415-420
27. Krall R.L., Penry J.K., Kupferberg H.J., and Swinyard E.A. Antiepileptic drug development: I. History and a program for progress. Epilepsia 19 4 (1978) 393-408
28. Kupferberg H.J. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 30 Suppl. 1 (1989) S51-56; discussion S64-68
29. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Eng. J. Med. 342 (2000) 314-319
30. Lehnertz K., Mormann F., Osterhage H., Müller A., Prusseit J., Chernihovskyi A., Staniek M., Krug D., Bialonski S., and Elger C.E. J. Clin. Neurophysiol. 24 2 (2007) 147-153
31. Lhatoo S.D., Wong I.C.K., Polizzi G., and Sander J.W.A.S. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 12 (2000) 1592-1596
32. Litt B., and Lehnertz K. Seizure prediction and the preseizure period. Curr. Opin. Neurol. 15 (2002) 173-177
33. Löscher W. Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find. Exp. Clin. Pharmacol. 6 9 (1984) 531-547
34. Löscher W., and Leppik I.E. Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs. Epilepsy Res. 50 (2002) 17-20
35. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., Williamson P.D., Treiman D.M., McNamara J.O., McCutchen C.B., Homan R.W., Crill W.E., Lubozynski M.F., Rosenthal N.P., and Mayersdorf A. Comparison of carbamazepine, Phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Eng. J. Med. 313 (1985) 145-151
36. Mattson R.H., Cramer J.A., and Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondaility generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N. Engl. J. Med. 327 11 (1992) 765-771
37. McLean M.J., Engstrom S., and Holcomb R.R. Magnetic field therapy for epilepsy. Brain Behav. 2 (2001) s81-s87
38. McLean M.J., Engstrom S., Holcomb R.R., and Sanchez D. A static magnetic field modulates severity of audiogenic seizures and anticonvulsant effects of phenytoin. Epilepsy Res. 55 (2003) 105-116
39. McMillan D.R., and White P.C. Loss of the transmembrane and cytoplasmic domains of the very large G-protein-coupled receptor-1 (VLGR1 or Mass1) causes audiogenic seizures in mice. Mol. Cell. Neurosci. 26 (2004) 322-329
40. Misawa H., Kawasaki Y., Melton J., Sweeney N., Jo K., Nicoll R.A., and Bredt D.S. Contrasting localizations of MALS/LIN-7 PDZ proteins in brain and molecular compensation in knockout mice. J. Biol. Chem. 276 (2001) 9264-9272
41. Misawa H., Sherr E.H., Lee D.J., Chetkovich D.M., Tan A., Schreiner C.E., and Bredt D.S. Identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice. J. Neurosci. 22 23 (2002) 10088-10093
42. Moraes M.F.D., CHavali M., Mishra P.K., Jobe P.C., and Garcia-Cairasco N. A comprehensive electrographic and behavioral analysis of generalized tonic-clonic seizures of GEPR-9s. Brain Res. 1033 (2005) 1-12
43. Němec P., Altmann J., Marhold S., Burda H., and Oelschläger. Neuroanatomy of magneoreception: the superior colliculus involve in magnetic orientation in a mammal. Science 294 (2001) 366-368
44. Pennacchio L.A., Lehesjoki A.E., Stone N.E., Willour V.L., Virtaneva K., Miao J., D'Amato E., Ramirez L., Faham M., Koskiniemi M., Warrington J.A., Norio R., de la Chapelle A., Cox D.R., and Myers R.M. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPMI). Science 271 (1996) 1731-1734
45. Peričić D., Švob D., Jazvinšćak M., and Mirković K. Anticonvulsant effect of swim stress in mice. Pharmacol. Biochem. Behav. 66 (2000) 879-886
46. Piazzini, A, Ramaglia, G, Turner, K, Chifari, R, Kiky, EE, Canger, R, Canevini, M.P. Coping strategies in epilepsy: 50 drug-resistant and 50 seizure-free patients. Seizure, 2007, Jan 5 [Epub ahead of print].
47. Puttagunta R., Gordon L.A., Meyer G.E., Kapfhamer D., Lamerdin J.E., Kantheti P., Portman K.M., Chung W.K., Jenne D.E., Olsen A.S., and Burmeister M. Comparative maps of human 19p13. 3 and mouse chromosome 10 allow identification of sequences at evolutionary breakpoints. Genome Res. 10 (2000) 1369-1680
48. Ross K.C., and Coleman J.R. Developmental genetic audiogenic seizure models: behavior and biological substrates. Neurosci. Behav. Rev. 24 (2000) 639-653
49. Rowan A.J., Ramsay R.E., Collins J.F., Pryor F., Boardman K.D., Uthman B.M., Spitz M., Frederick T., Towne A., Carter G.S., Marks W., Felicetta J., and Tomyanovich M.L. VA Cooperative Study 428 Group. New onset geriatric epilepsy A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64 (2005) 1868-1873
50. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. (2002) 1-12
51. Schmidt D., and Löscher W. How effective is surgery to cure seizures in drug-resistant temporal lobe epilepsy?. Epilepsy Res. 56 (2003) 85-91
52. Schmidt D., Baumgartner C., and Löscher W. Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: A review of current clinical experience. Epilepsia 45 2 (2004) 179-186
53. Skradski S.L., Clark A.M., Jiang H., White H.S., Fu Y.H., and Ptacek L.J. A novel gene causing a Mendelian audiogenic mouse epilepsy. Neuron 31 (2001) 537-544
54. Skradski S.L., White H.S., and Ptacek L.J. Genetic mapping of a locus (mass1) causing audiogenic seizures in mice. Genomics 49 (1998) 188-192
55. Smith D.B., Mattson R.H., Cramer J.A., Collins J.F., Novelly R.A., and Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, Phenobarbital, phenytoin and primidone. Epilepsia 28 Suppl. 3 (1987) S50-S58
56. Smith M., Wilcox K.S., and White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 4 1 (2007) 12-17
57. Spencer S.S. When should temporal-lobe epilepsy be treated surgically?. Lancet Neurol. 1 (2002) 375-382l
58. Stables J.P., Bertram E.H., White H.S., Coulter D.A., Dichter M.A., Jacobs M.P., Loscher W., Lowenstein D.H., Moshe S.L., Noebels J.L., and Davis M. Models for epilepsy and epileptogenisis: report from the NIH Workshop, Bethesda, Maryland. Epilepsia 43 11 (2002) 1410-1420
59. Tchekalarova J., and Georiev V. Effect of acute versus chronic theophylline administration on acute restraint stress-induced increase of pentylenetetrazol seizure threshold in mice. Brain Res. Bull. 68 (2006) 464-468.l
60. Theodore W.H., Spencer S.S., Wiebe S., Langfitt J.T., Ali A., Shafer P.O., Berg A.T., and Vickrey B.G. ILAE Report: Epilepsy in North America: A report prepared under the auspices of the Global Campaign Against Epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia 47 10 (2006) 1700-1722
61. White H.S., Wolf H.H., Woodhead J.H., and Kupferberg H.J. The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. Adv. Neurol. 76 (1998) 29-39
62. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., and Wolf HH. General principles. Discovery and preclinical development of antiepileptic drugs. Antiepileptic Drugs. Fifth Ed. (2002) Chapter 3
63. Yagi H., Takamura Y., Yoneda T., Konno D., Akagi Y., Yoshida K., and Sato M. Vlgr1 knockout mice show audiogenic seizure susceptibility. J. Neurochem. 92 (2005) 191-202
64. Zheng Q.Y., Johnson K.R., and Erway L.C. Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hearing Res. 130 (1999) 94-107
65. Zhou X., Jen P.H.-S., Seburn K.L., Frankel W.N., and Zheng Q.Y. Auditory brainstem responses in 10 inbred strains of mice. Brain Res. 1091 (2006) 16-26